Akari Therapeutics, Plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 2834 www.akaritx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics, Plc

European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading - May 7th, 2026 9:10 am
European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday Trading - May 6th, 2026 9:10 am
European Equities Traded in the US as American Depositary Receipts Start Week Lower - May 4th, 2026 9:09 am
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week - May 1st, 2026 9:10 am
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - Apr 29th, 2026 9:05 am
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading - Apr 27th, 2026 9:17 am
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload - Apr 27th, 2026 6:35 am
European Equities Traded in US as ADRs Ease in Thursday Trading - Apr 23rd, 2026 9:04 am
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading - Apr 22nd, 2026 9:13 am
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading - Apr 21st, 2026 9:14 am
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors - Apr 21st, 2026 7:00 am
Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital Needs - Apr 20th, 2026 8:47 pm
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing - Apr 20th, 2026 6:35 am
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - Apr 10th, 2026 9:14 am
Akari Therapeutics downgraded to Hold from Buy at Maxim - Apr 10th, 2026 7:05 am
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - Apr 9th, 2026 6:50 am
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading - Apr 8th, 2026 9:03 am
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading - Apr 6th, 2026 9:06 am
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing - Apr 6th, 2026 6:45 am
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - Apr 2nd, 2026 9:09 am